Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 19/20 | 0.55 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
| ▸ | CTSS | P25774 | 1/20 | 0.46 |
| ▸ | TACR3 | P29371 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30133574 | 0.85 | CAPN1 (0.60) | CAPN1CTSLCTSBCTSS | |
| SCHEMBL20027691 | 0.85 | CAPN1 (0.60) | CAPN1CTSLCTSBCTSS | |
| SCHEMBL22896478 | 0.84 | CAPN1 (0.61) | CAPN1CTSS | |
| SCHEMBL22896944 | 0.83 | CAPN1 (0.60) | CAPN1CTSS | |
| SCHEMBL22897077 | 0.83 | CAPN1 (0.57) | CAPN1CTSLCTSBCTSS | |
| SCHEMBL20028416 | 0.82 | CAPN1 (0.56) | CAPN1CTSLCTSBCTSSTACR3 | |
| SCHEMBL22896485 | 0.82 | CAPN1 (0.56) | CAPN1CTSS | |
| SCHEMBL22896873 | 0.80 | CAPN1 (0.57) | CAPN1CTSS | |
| SCHEMBL20028406 | 0.80 | CAPN1 (0.54) | CAPN1CTSLCTSBCTSSTACR3 | |
| SCHEMBL22896584 | 0.78 | CAPN1 (0.55) | CAPN1CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-10934261-B2 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-10894776-B2 | — | — | 2021-01-19 | — | — | US | disclosed |
| WO-2018064119-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPEUTICS, INC. (US) | 2018-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10934261-B2 | Calpain modulators and therapeutic uses thereof | CAPNS1, CAPN9, CAPN1 | CAPN1 3/4885CTSL 234/4885CTSB 105/4885 |
| US-10894776-B2 | — | CAPNS1, CAPN9, CAPN2 | CAPN1 4/4885CTSL 242/4885CTSB 193/4885 |
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | CAPNS1, CAPN9, CAPN1 | CAPN1 3/4885CTSL 234/4885CTSB 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.